LIPOSOMAL DAUNORUBICIN OVERCOMES DRUG RESISTANCE IN HUMAN BREAST, OVARIAN AND LUNG CARCINOMA CELLS
Abstract
Multi-drug resistance due in part to membrane pumps such as P-glycoprotein (Pgp) is a major clinical problem in human cancers. We tested the ability of liposomally-encapsulated daunorubicin (DR) to overcome resistance to this drug. A widely used breast carcinoma cell line originally selected for resistance in doxorubicin (MCF7ADR) was 4-fold resistant to DR compared to the parent MCF7 cells (IC50 79 nM vs. 20 nM). Ovarian carcinoma cells (SKOV3) were made resistant by retroviral transduction of MDR1 cDNA and selection in vinblastine. The resulting SKOV3MGP1 cells were 130-fold resistant to DR compared to parent cells (IC50 5700 nM vs. 44 nM). Small-cell lung carcinoma cells (H69VP) originally selected for resistance to etoposide were 6-fold resistant to DR compared to H69 parent cells (IC50 180 nM vs. 30 nM). In all three cases, encapsulation of DR in liposomes as Daunoxome (Gilead) did not change the IC50 of parent cells relative to free DR. However, liposomal DR overcame resistance in MCF7ADR breast carcinoma cells (IC50 20 nM), SKOV3MGP1 ovarian carcinoma cells (IC50 237 nM) and H69VP small-cell lung carcinoma cells (IC50 27 nM). Empty liposomes did not affect the IC50 for free DR in the three resistant cell lines, nor did empty liposomes affect the IC50 for other drugs that are part of the multi-drug resistance phenotype (etoposide, vincristine) in lung carcinoma cells. These data indicate the possible value of liposomal DR in overcoming Pgp-mediated drug resistance in human cancer.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
DaunoXome (daunorubicin liposomes) showed better therapeutic efficacy against Kaposi's sarcoma and other tumors.
“DaunoXome (daunorubicin liposomes) showed better therapeutic efficacy against Kaposi’s sarcoma and other tumors.241”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [241]
Cites
Batist, G., Tulpule, A., Sinha, B. K., Katki, A. G., Myers, C. E., & Cowan, K. H. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)66748-1 · Cited by 790 · see citing works
Muggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P. J., Groshen, S. G., Tan, M., Roman, L., Uziely, B., Muderspach, L. I., Garcia, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.987 · Cited by 646 · see citing works
Trock, B. J., Leonessa, F., & Clarke, R. C. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.13.917 · Cited by 434 · see citing works
Goren, D., Horowitz, A. T., Tzemach, D., Tarshish, M., Zalipsky, S., & Gabizón, A. (2000) · PubMed · Cited by 402 · see citing works
Gordon, A. N., Granai, C. O., Rose, P. G., Hainsworth, J. D., Lopez, A. B., Weissman, C., Rosales, R., & Sharpington, T. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3093 · Cited by 336 · see citing works
Itakura, J., Ishiwata, T., Shen, B., Kornmann, M., & Korc, M. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000101)85:1 · Cited by 242 · see citing works
Liposomes in biological systems
ALLISON, A. C., & Gregoriadis, G. C. (1980) · Medical Entomology and Zoology · Cited by 190 · see citing works
Liposomes as Tools in Basic Research and Industry (1994)
(2017) · CRC Press eBooks · doi:10.1201/9780203713259 · Cited by 181 · see citing works
Legrand, O., Simonin, G., Beauchamp‐Nicoud, A., Zittoun, R., & Marie, J. (1999) · Blood · doi:10.1182/blood.v94.3.1046.415k03_1046_1056 · Cited by 178 · see citing works
Liposomes in biological systems
Fleming, P. J. (1980) · Cell · doi:10.1016/0092-8674(80)90500-0 · Cited by 116 · see citing works
Liposome-Mediated Modulation of Multidrug Resistance in Human HL-60 Leukemia Cells
Rahman, A., Husain, S. R., Siddiqui, J. I., Verma, M., Agresti, M., Safa, A. R., & Glazer, R. I. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.24.1909 · Cited by 104 · see citing works
Valero, V., Buzdar, A. U., Theriault, R. L., Azarnia, N., Fonseca, G. A., Willey, J. S., Ewer, M. S., Walters, R. S., Mackay, B., Podoloff, D. A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1425 · Cited by 85 · see citing works
Drug resistance in lung cancer
Nishio, K., Nakamura, T., Koh, Y., Suzuki, T., Fukumoto, H., & Saijo, N. (1999) · Current Opinion in Oncology · doi:10.1097/00001622-199903000-00006 · Cited by 72 · see citing works
Chemotherapy resistance in ovarian cancer: New molecular perspectives
Coukos, G. (1998) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(98)00054-4 · Cited by 69 · see citing works
Characterization of an etoposide-resistant human small-cell lung cancer cell line
Minato, K., Kanzawa, F., Nishio, K., Nakagawa, K., Fujiwara, Y., & Saijo, N. (1990) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf02897284 · Cited by 68 · see citing works
Liposomes as Vehicles for Targeted Therapy of Cancer. Part 2: Clinical Development
Harrington, K. J., Lewanski, C. R., & Stewart, J. S. W. (2000) · Clinical Oncology · doi:10.1053/clon.2000.9105 · Cited by 55 · see citing works
Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs.
Aszalós, A., & Ross, D. D. (1998) · PubMed · Cited by 54 · see citing works
Liposome‐encapsulated daunorubicin for PGP‐related multidrug resistance
Michieli, M., Damiani, D., Ermacora, A., Masolini, P., Michelutti, A., Michelutti, T., Russo, D., Pea, F., & Baccarani, M. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01505.x · Cited by 52 · see citing works
Zucchetti, M., Boiardi, A., Silvani, A., Parisi, I., Piccolrovazzi, S., & D’Incalci, M. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050964 · Cited by 50 · see citing works
Chemotherapy resistance in breast cancer.
Lehnert, M. (1998) · PubMed · Cited by 43 · see citing works
Drug resistance in ovarian cancer: from the laboratory to the clinic
Sood, A. K. (1998) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(98)00184-7 · Cited by 35 · see citing works
Richardson, D. S., Kelsey, S. M., Johnson, S. A., Tighe, M., Cavenagh, J. D., & Newland, A. C. (1997) · Investigational New Drugs · doi:10.1023/a:1005879219554 · Cited by 34 · see citing works
Krishna, R., & Mayer, L. D. (2000) · PubMed · Cited by 28 · see citing works
Wang, Y., Eksborg, S., Lewensohn, R., Lindberg, A., & Liliemark, E. (1999) · Anti-Cancer Drugs · doi:10.1097/00001813-199911000-00008 · Cited by 28 · see citing works
Liposomal formulations of cytotoxic drugs
Janknegt, R. (1996) · Supportive Care in Cancer · doi:10.1007/bf01358884 · Cited by 25 · see citing works
Uthayakumar, S., Bower, M., Money‐Kyrle, J., Muyshondt, C., Youle, M. S., Hannon, F., Phillips, R., Gazzard, B., & Boag, F. (1996) · AIDS · doi:10.1097/00002030-199605000-00010 · Cited by 24 · see citing works
Liposomal daunorubicin: in vitro and in vivo efficacy in multiple myeloma
Pratt, G., Wiles, M. E., Rawstron, A. C., Davies, F. E., Fenton, J. A. L., Proffitt, J. A., Child, J. A., Smith, G., & Morgan, G. J. (1998) · Hematological Oncology · doi:10.1002/(sici)1099-1069(199806)16:2 · Cited by 23 · see citing works
Verdonck, L. F., Lokhorst, H. M., Roovers, D. J., & van Heugten, H. G. (1998) · Leukemia Research · doi:10.1016/s0145-2126(97)00160-4 · Cited by 22 · see citing works
Metz, M. Z., Best, D. M., & Kane, S. E. (1995) · Virology · doi:10.1006/viro.1995.1194 · Cited by 22 · see citing works
Self-citationYeo, W., Chan, K. K., Mukwaya, G., Ross, M. B., Leung, W. T., Ho, S. K. W., Chan, A. T. �., & Johnson, P. J. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050956 · Cited by 21 · see citing works
Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer
Pusztai, L., Esteva, F. J., Cristofanilli, M., & Hung, M. (1999) · Cancer Treatment Reviews · doi:10.1053/ctrv.1999.0132 · Cited by 20 · see citing works
Resistance mechanisms in human lung cancer.
Mattern, J., & Volm, M. (1995) · PubMed · Cited by 15 · see citing works
Liposome encapsulated daunorubicin (daunoxome) for acute leukemia.
Ermacora, A., Michieli, M., Pea, F., Visani, G., Bucalossi, A., & Russo, D. (2000) · PubMed · Cited by 13 · see citing works
Characterization of an etoposide-resistant human small-cell lung cancer cell line
湊, 浩. (1991) · Medical Entomology and Zoology · doi:10.11501/3053609 · Cited by 5 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,784 · see citing works
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645 · see citing works
Microfluidic Directed Formation of Liposomes of Controlled Size
Jahn, Α., Vreeland, W. N., DeVoe, D. L., Locascio, L. E., & Gaitan, M. (2007) · Langmuir · doi:10.1021/la070051a · Cited by 428 · see citing works
Binkhathlan, Z., & Lavasanifar, A. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990076 · Cited by 390 · see citing works
New frontiers in nanotechnology for cancer treatment
Alexis, F., Rhee, J., Richie, J. P., Radovic‐Moreno, A. F., Langer, R., & Farokhzad, O. C. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.017 · Cited by 359 · see citing works
Nanomedicinal Strategies to Treat Multidrug-Resistant Tumors: Current Progress
Dong, X., & Mumper, R. J. (2010) · Nanomedicine · doi:10.2217/nnm.10.35 · Cited by 314 · see citing works
Preparation of nanoparticles by continuous-flow microfluidics
Jahn, Α., Reiner, J. E., Vreeland, W. N., DeVoe, D. L., Locascio, L. E., & Gaitan, M. (2008) · Journal of Nanoparticle Research · doi:10.1007/s11051-007-9340-5 · Cited by 260 · see citing works
Lehner, R., Wang, X., Marsch, S. C. U., & Hunziker, P. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.01.012 · Cited by 221 · see citing works
Pillai, G. (2014) · SOJ Pharmacy & Pharmaceutical Sciences · doi:10.15226/2374-6866/1/2/00109 · Cited by 217 · see citing works
Kaminskas, L. M., McLeod, V. M., Kelly, B. D., Sberna, G., Boyd, B. J., Williamson, M., Owen, D. J., & Porter, C. J. H. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.05.013 · Cited by 178 · see citing works
Stewart, D. J. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.11.006 · Cited by 174 · see citing works
Gold-doxorubicin nanoconjugates for overcoming multidrug resistance
Gu, Y.-J., Cheng, J., Man, C., Wong, W., & Cheng, S. H. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.06.005 · Cited by 171 · see citing works
In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors
Koziara, J. M., Whisman, T. R., Tseng, M. T., & Mumper, R. J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.03.001 · Cited by 155 · see citing works
Johnston, M., Semple, S. C., Klimuk, S. K., Edwards, K., Eisenhardt, M. L., Leng, E. C., Karlsson, G., Yanko, D., & Cullis, P. R. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.01.009 · Cited by 152 · see citing works
Pillai, G. (2014) · SOJ Pharmacy & Pharmaceutical Sciences · doi:10.15226/2374-6866/1/1/00109 · Cited by 135 · see citing works
Risinger, A. L., Jackson, E. M., Polin, L., Helms, G. L., LeBoeuf, D. A., Joe, P. A., Hopper-Borge, E. A., Ludueña, R. F., Kruh, G. D., & Mooberry, S. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2037 · Cited by 124 · see citing works
Design and Biological Evaluation of Cell-Penetrating Peptide–Doxorubicin Conjugates as Prodrugs
Shirazi, A. N., Tiwari, R. K., Chhikara, B. S., Mandal, D., & Parang, K. (2013) · Molecular Pharmaceutics · doi:10.1021/mp3004034 · Cited by 116 · see citing works
Drug Delivery Systems for Intraperitoneal Therapy
Bajaj, G., & Yeo, Y. (2010) · Pharmaceutical Research · doi:10.1007/s11095-009-0031-z · Cited by 110 · see citing works
Du, L., Robles, A. J., King, J. B., Powell, D. R., Miller, A. N., Mooberry, S. L., & Cichewicz, R. H. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201306549 · Cited by 101 · see citing works
pH-Responsive Nanoparticles for Cancer Drug Delivery
Shen, Y., Tang, H., Radosz, M., Kirk, E. V., & Murdoch, W. J. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-210-6_10 · Cited by 93 · see citing works
Smet, L. D., Ceelen, W. P., Remon, J. P., & Vervaet, C. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/720858 · Cited by 93 · see citing works
Tumour-selective drug delivery via folate receptor-targeted liposomes
Pan, X., & Lee, R. J. (2004) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.1.1.7 · Cited by 75 · see citing works
Kaminskas, L. M., McLeod, V. M., Kelly, B. D., Cullinane, C. M., Sberna, G., Williamson, M., Boyd, B. J., Owen, D. J., & Porter, C. J. H. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200522d · Cited by 73 · see citing works
Pinto, A., & Pocard, M. D. (2018) · Pleura and Peritoneum · doi:10.1515/pp-2018-0124 · Cited by 72 · see citing works
Pillai, G., & Ceballos-Coronel, M. L. (2013) · SAGE Open Medicine · doi:10.1177/2050312113513759 · Cited by 67 · see citing works
Fojo, T., & Coley, H. M. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.n.035 · Cited by 62 · see citing works
Nanotechnology Toward Treating Cancer
Pillai, G. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814029-1.00009-0 · Cited by 57 · see citing works
Liposome-coated nano doxorubicin induces apoptosis on oral squamous cell carcinoma CAL-27 cells
Elhamid, E. S. A., Gamal‐Eldeen, A. M., & Eldeen, A. M. S. (2019) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2019.05.011 · Cited by 48 · see citing works
Delivering flavonoids into solid tumors using nanotechnologies
Wang, S., Zhang, J., Chen, M., & Wang, Y. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.807795 · Cited by 45 · see citing works
Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides
Simón‐Gracia, L., Hunt, H., & Teesalu, T. (2018) · Molecules · doi:10.3390/molecules23051190 · Cited by 44 · see citing works
Charest, G., Paquette, B., Fortin, D., Mathieu, D., & Sanche, L. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0011-5 · Cited by 42 · see citing works
How can nanomedicines overcome cellular-based anticancer drug resistance?
Sobot, D., Mura, S., & Couvreur, P. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb00900j · Cited by 40 · see citing works
Shaik, M. S., Chatterjee, A., & Singh, M. S. (2004) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357023772 · Cited by 37 · see citing works
Plasmin-Loaded Echogenic Liposomes for Ultrasound-Mediated Thrombolysis
Kandadai, M. A., Meunier, J. M., Hart, K., Holland, C. K., & Shaw, G. J. (2014) · Translational Stroke Research · doi:10.1007/s12975-014-0376-4 · Cited by 36 · see citing works
The Use of Anthracyclines for Therapy of CNS Tumors
Ros, M. D., Iorio, A. L., Lucchesi, M., Stival, A., de Martino, M., & Sardi, I. (2015) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520615666150407155319 · Cited by 33 · see citing works
Mozaffari, S., Salehi, D., Mahdipoor, P., Beuttler, R., Tiwari, R. K., Aliabadi, H. M., & Parang, K. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113836 · Cited by 30 · see citing works
Khan, M. A., Khan, A. A., Dwivedi, V., Ahmad, M., Hakeem, S., & Owais, M. (2007) · Molecular Medicine · doi:10.2119/2007-00018.khan · Cited by 26 · see citing works
Cytotoxic Dimeric Epipolythiodiketopiperazines from the Ascomycetous Fungus Preussia typharum
Du, L., Robles, A. J., King, J. B., Mooberry, S. L., & Cichewicz, R. H. (2014) · Journal of Natural Products · doi:10.1021/np5002253 · Cited by 24 · see citing works
Małek, A., Taciak, B., Dobruch‐Sobczak, K., Grzelak, A., Wójcik, M., Mieczkowski, J. B., Lechowski, R., & Zabielska-Koczywąs, K. A. (2021) · Molecules · doi:10.3390/molecules26123487 · Cited by 24 · see citing works
CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?
Brunetti, C., Anelli, L., Zagaria, A., Specchia, G., & Albano, F. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1369400 · Cited by 23 · see citing works
Lee, J., Lee, M. G., Jung, C., Park, Y.-H., Song, C., Choi, M. C., Park, H. G., & Park, J. (2013) · BioChip Journal · doi:10.1007/s13206-013-7303-8 · Cited by 20 · see citing works
Du, L., Robles, A. J., King, J. B., Powell, D. R., Miller, A. N., Mooberry, S. L., & Cichewicz, R. H. (2013) · Angewandte Chemie · doi:10.1002/ange.201306549 · Cited by 19 · see citing works
Grabarnick, E., Andriyanov, A. V., Han, H., Eyal, S., & Barenholz, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122181 · Cited by 18 · see citing works
Bismuth nitrate-induced novel nitration of estradiol: An entry to new anticancer agents
Bandyopadhyay, D., Rivera, G., Sanchez, J. L., Rivera, J., Granados, J. C., Guerrero, A. M., Chang, F.-M., Dearth, R. K., Short, J. D., & Banik, B. K. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.06.010 · Cited by 18 · see citing works
Frega, S., Bonanno, L., Guarneri, V., Conte, P., & Pasello, G. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.05.013 · Cited by 14 · see citing works
In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles
Abreu, T. R., Biscaia-Caleiras, M., Gonçalves, N., Fonseca, N. A., & Moreira, J. N. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_12 · Cited by 13 · see citing works
Huang, Y., Peng, H., Zeng, A., & Song, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1188477 · Cited by 12 · see citing works
Homogeneous and reproducible liposome preparation relying on reassembly in microchannel laminar flow
Yamashita, K., Nagata, M. P. B., Miyazaki, M., Nakamura, H., & Maeda, H. (2010) · Chemical Engineering Journal · doi:10.1016/j.cej.2010.09.007 · Cited by 10 · see citing works
Mohammadi, S., Zakeri‐Milani, P., Golkar, N., Farkhani, S. M., Shirani, A., Mojarrad, J. S., Nokhodchi, A., & Valizadeh, H. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1379016 · Cited by 9 · see citing works
Design, synthesis and biological evaluation of novel pyrenyl derivatives as anticancer agents
Bandyopadhyay, D., Sanchez, J. L., Guerrero, A. M., Chang, F.-M., Granados, J. C., Short, J. D., & Banik, B. K. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.072 · Cited by 8 · see citing works
Mitchell, P. L. R., Marlton, P. V., Grigg, A., Seymour, J. F., Hertzberg, M., Enno, A., Herrmann, R., Bond, R., & Arthur, C. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802007700 · Cited by 8 · see citing works
New Treatment Modalities for the Management of Peritoneal Metastases
Bhatt, A., & Mehta, A. (2017) · Springer eBooks · doi:10.1007/978-981-10-7053-2_20 · Cited by 4 · see citing works
Dong, X. (2009) · UKnowledge (University of Kentucky) · Cited by 3 · see citing works
Triphenylmethanol Conjugates of Triptorelin as Anti-Lipid Peroxidation Prodrugs
Alhamed, S., Alnakhli, J., Boadi, W. Y., & Beni, R. (2019) · Open Journal of Medicinal Chemistry · doi:10.4236/ojmc.2019.93003 · Cited by 3 · see citing works
Liposomal nano-formulations: advancement in lung cancer treatment
Ashraf, A., Ain, Q., Qamar, A., Nisar, A., Arshad, S., Asim, M. H., & Irfan, H. M. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120813 · Cited by 2 · see citing works
Poly(propylene sulfide) nanoparticles as drug carriers
Rehor, A. (2005) · Repository for Publications and Research Data (ETH Zurich) · doi:10.3929/ethz-a-004907963 · Cited by 2 · see citing works
Triphenylmethanol Conjugates of Triptorelin as Cell-Penetrating Anti-Cancer Prodrugs
Alnakhli, J., Alhamed, S., Boadi, W. Y., & Beni, R. (2023) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2023.1111018 · Cited by 1 · see citing works
Mitochondria-targeted Doxorubicin is Active and Resistant to Drug Efflux
Chamberlain, G. R. (2012) · TSpace (University of Toronto) · Cited by 1 · see citing works
Gharib, M. I., & Burnett, A. K. (2006) · Springer eBooks · doi:10.1007/0-387-31056-8_78 · Cited by 1 · see citing works
Basics of Targeted Drug Delivery
Doshi, K. A. (2022) · Methods and principles in medicinal chemistry · doi:10.1002/9783527827855.ch1 · Cited by 1 · see citing works
Chapter 24: Gold‒Doxorubicin Nanoconjugates for Overcoming Multidrug Resistance
Rahimi, M., Wadajkar, A. S., Subramanian, K., Yousef, M., Cui, W., Hsieh, J., & Nguyen, K. T. (2017) · CRC Press eBooks · doi:10.1201/9781315114361-25
QSAR model for the evaluation of biological active molecules on estrogen positive breast cancerPreprint
Mercado‐Sánchez, I., Vargas-Rodríguez, I., Chávez‐Rocha, R., Fonseca-Yepez, C., García-Tejada, E. P., Vazquez, M. A., Bazán‐Jiménez, A., Robles, J., & Garcia-Revilla, M. A. (2026) · Research Square · doi:10.21203/rs.3.rs-9952743/v1
- Authors
- Sadava, D., Coleman, A., & Kane, S. E.
- Affiliations
- W.M. Keck Science Center (US)
- City Of Hope National Medical Center (US)
- Venue
- Journal of Liposome Research
- Publisher
- Informa UK Limited
- Published
- 2002-01
- Volume
- 12
- Issue
- 4
- Pages
- 301-309
- ISSN
- 0898-2104 (ISSN-L)
- 1532-2394
- OpenAlex
- W2098831599
- Cited by
- 63
- References
- 34
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 2 · 2022: 1 · 2021: 4 · 2019: 3 · 2018: 4 · 2017: 4 · 2016: 1 · 2015: 1 · 2014: 6 · 2013: 10 · 2012: 2
- FWCI
- 0.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Liposome Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- J.B. and M.K. Pritzker Family Foundation
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- daunorubicin, liposomal drug delivery, multidrug resistance, P-glycoprotein, MDR1, breast cancer, ovarian carcinoma, small cell lung cancer, DaunoXome, etoposide resistance, vincristine resistance
- MeSH terms
- Antineoplastic Agents, Breast Neoplasms, Daunorubicin, Female, Humans, Liposomes, Lung Neoplasms, Ovarian Neoplasms, Tumor Cells, Cultured, Cell Death, Carcinoma, Small Cell, Drug Resistance, Neoplasm, Inhibitory Concentration 50
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
